Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced a strategic, multi-year a (SIH), a regional leader in healthcare delivery and the largest health ...

New England Journal of Medicine Publishes eNRGy Trial Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

February is National Heart Month, and doctors are stressing the importance of preventing the disease. Experts say heart disease has been the leading cause of death across the United States since 1950, ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

The most common cardiovascular killer in maternal medicine is also among the most misdiagnosed. Peripartum cardiomyopathy ...

In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Investors interested in arranging a meeting with the Company's management during the conference can register on the BIO CEO & Investor Conference website here.

It’s Women’s Heart Health Month, and experts are raising awareness about heart disease in hopes of saving lives. Feeling ...

Regular screenings for all patients should begin at age 20 and proceed in intervals. However, if you're at high risk for ...

STERMI/chest pain coordinator stops by the TV6 studio to talk about the differences between men and women in a heart ...

Moderate-to-severe tricuspid regurgitation (TR) has a high prevalence in the general population, 1 and it progressively increases in older individuals, in whom it is close to 4%.